TY - JOUR
T1 - Fat absorption and gastroenteric ph profile in postsurgical pancreatic insufficiency
T2 - Role of the association of H2-receptor antagonists with pancreatic enzymes
AU - Braga, Marco
AU - Zerbi, Alessandro
AU - Malesci, Alberto
AU - Dal Cin, Stefano
AU - Valentini, Angela
AU - Tacconi, Milena
AU - Erenbourg, Luciano
AU - Paganelli, Michele
AU - Di Carlo, Valerio
PY - 1993
Y1 - 1993
N2 - The complete control of steatorrhea in postsurgical exocrine pancreatic insufficiency is difficult. The aim of this study was to evaluate the effect of the association of ranitidine with pancrelipase on fecal fat excretion in patients who had undergone a pancreatoduodenectomy with suppression of the exocrine pancreatic secretion by Neoprene injection. Ten patients were studied 1 year after surgery. Steatorrhea was measured as an integrated test of 3-day stools, while patients were kept on a diet of 100 g lipid/day, with their usual enzyme supplementation therapy (16,050 USP units of lipase/meal). A basal 24-h gastroenteric pH profile was also obtained. In the following month, patients had ranitidine (150 mg twice a day) in addition to pancrelipase. Then steatorrhea and gastroenteric pH were reassessed. Mean fecal fat was 26.9 (SD 13.7) g/day without ranitidine and 30.5 (SD 13.9) g/day during combined treatment. Body weight and nutritional parameters did not show any significant variation after ranitidine administration. Even in the absence of ranitidine, postprandial gastroenteric pH values were always >4; the H2-receptor antagonist only reduced fasting gastric acidity. In conclusion, the gastroenteric pH and fecal fat determinations showed that ranitidine is not useful in patients with total postsurgical exocrine pancreatic insufficiency.
AB - The complete control of steatorrhea in postsurgical exocrine pancreatic insufficiency is difficult. The aim of this study was to evaluate the effect of the association of ranitidine with pancrelipase on fecal fat excretion in patients who had undergone a pancreatoduodenectomy with suppression of the exocrine pancreatic secretion by Neoprene injection. Ten patients were studied 1 year after surgery. Steatorrhea was measured as an integrated test of 3-day stools, while patients were kept on a diet of 100 g lipid/day, with their usual enzyme supplementation therapy (16,050 USP units of lipase/meal). A basal 24-h gastroenteric pH profile was also obtained. In the following month, patients had ranitidine (150 mg twice a day) in addition to pancrelipase. Then steatorrhea and gastroenteric pH were reassessed. Mean fecal fat was 26.9 (SD 13.7) g/day without ranitidine and 30.5 (SD 13.9) g/day during combined treatment. Body weight and nutritional parameters did not show any significant variation after ranitidine administration. Even in the absence of ranitidine, postprandial gastroenteric pH values were always >4; the H2-receptor antagonist only reduced fasting gastric acidity. In conclusion, the gastroenteric pH and fecal fat determinations showed that ranitidine is not useful in patients with total postsurgical exocrine pancreatic insufficiency.
KW - Gastroenteric pH profile
KW - H2-Receptor antagonist
KW - Neoprene
KW - Pancreatoduodenectomy
KW - Pancrelipase
KW - Steatorrhea
UR - http://www.scopus.com/inward/record.url?scp=0027297656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027297656&partnerID=8YFLogxK
M3 - Article
C2 - 8103218
AN - SCOPUS:0027297656
SN - 0885-3177
VL - 8
SP - 494
EP - 498
JO - Pancreas
JF - Pancreas
IS - 4
ER -